Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion

Background. Despite the dose-dependent response rate of sarcomas to doxorubicin, clinicians limit its cumulative dose due to cardiotoxicity. This study evaluates early evidence of cardiotoxicity in patients treated with high-dose doxorubicin given as a continuous infusion. Methods. Data was collecte...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Raymundo A. Quintana, Jose Banchs, Ridhi Gupta, Heather Y. Lin, Sean D. Raj, Anthony Conley, Vinod Ravi, Dejka Araujo, Robert S. Benjamin, Shreyaskumar Patel, Saroj Vadhan-Raj, Neeta Somaiah
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Hindawi Limited 2017-01-01
Saila:Sarcoma
Sarrera elektronikoa:http://dx.doi.org/10.1155/2017/7495914
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak